Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label, Phase 1b/2 Study to Evaluate Intravenous Administration With Long Dosing Interval Regimens of Sarilumab in Adult Participants With Rheumatoid Arthritis

NCT07704580 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07704580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07704580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label, Phase 1b/2 Study to Evaluate Intravenous Administration With Long Dosing Interval Regimens of Sarilumab in Adult Participants With Rheumatoid Arthritis
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 2, 2026
Completion date
October 26, 2028
Enrollment
140 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis